Hepatitis C Assay Receives European In Vitro Diagnostic Test Certification
By LabMedica International staff writers Posted on 27 Apr 2015 |
Laboratories that adhere to the European Directive on In Vitro Diagnostic Medical Devices will now be able to work with a quantitative test that provides on-demand molecular testing for confirmation of infection and monitoring of Hepatitis C virus (HCV).
The Cepheid (Sunnyvale, CA, USA) Xpert HCV Viral Load assay was recently awarded CE IVD mark status under the European Directive. The test was designed to run on the Cepheid GeneXpert System, one of the world's leading molecular diagnostic platforms with over 8,000 systems deployed globally in both developed and emerging market countries.
Cepheid's GeneXpert System is a closed, self-contained, fully-integrated, and automated platform that combines on-board sample preparation with real-time PCR (polymerase chain reaction) amplification and detection functions for fully integrated and automated nucleic acid analysis. The system is designed to purify, concentrate, detect, and identify targeted nucleic acid sequences thereby delivering answers directly from unprocessed samples.
The Xpert HCV Viral Load assay is intended for use as an aid in the management of HCV infected patients undergoing antiviral therapy. The test can be used to measure HCV RNA levels at baseline and during treatment, and to help predict virological responses to HCV therapy. In addition, the test can be used for confirmation of HCV serologic test results.
"Existing HCV viral load tests run on complex systems that require highly-trained technicians to operate, and generally lack the flexibility to provide on-demand answers when required," said John Bishop, chairman and CEO of Cepheid. "Xpert HCV Viral Load, our 21st CE-IVD Xpert test, provides reliable results in less than two hours, making it a valuable tool for clinicians in the management of HCV infected patients on antiviral therapy."
"The Xpert HCV Viral Load test incorporates a number of novel technologies including our "BigTube" design, which allows us to take full advantage of the efficiency of integrated GeneXpert cartridge fluidics," said Dr. David H. Persing, CMO and CTO at Cepheid. "This helps us to avoid dead volume losses incurred with competitive first generation systems and to achieve unprecedented sensitivity levels for detection of HCV RNA."
Related Links:
Cepheid
The Cepheid (Sunnyvale, CA, USA) Xpert HCV Viral Load assay was recently awarded CE IVD mark status under the European Directive. The test was designed to run on the Cepheid GeneXpert System, one of the world's leading molecular diagnostic platforms with over 8,000 systems deployed globally in both developed and emerging market countries.
Cepheid's GeneXpert System is a closed, self-contained, fully-integrated, and automated platform that combines on-board sample preparation with real-time PCR (polymerase chain reaction) amplification and detection functions for fully integrated and automated nucleic acid analysis. The system is designed to purify, concentrate, detect, and identify targeted nucleic acid sequences thereby delivering answers directly from unprocessed samples.
The Xpert HCV Viral Load assay is intended for use as an aid in the management of HCV infected patients undergoing antiviral therapy. The test can be used to measure HCV RNA levels at baseline and during treatment, and to help predict virological responses to HCV therapy. In addition, the test can be used for confirmation of HCV serologic test results.
"Existing HCV viral load tests run on complex systems that require highly-trained technicians to operate, and generally lack the flexibility to provide on-demand answers when required," said John Bishop, chairman and CEO of Cepheid. "Xpert HCV Viral Load, our 21st CE-IVD Xpert test, provides reliable results in less than two hours, making it a valuable tool for clinicians in the management of HCV infected patients on antiviral therapy."
"The Xpert HCV Viral Load test incorporates a number of novel technologies including our "BigTube" design, which allows us to take full advantage of the efficiency of integrated GeneXpert cartridge fluidics," said Dr. David H. Persing, CMO and CTO at Cepheid. "This helps us to avoid dead volume losses incurred with competitive first generation systems and to achieve unprecedented sensitivity levels for detection of HCV RNA."
Related Links:
Cepheid
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia